B-intervention	0	10	Lumpectomy
I-intervention	11	15	plus
I-intervention	16	25	tamoxifen
I-intervention	26	30	with
I-intervention	31	33	or
I-intervention	34	41	without
I-intervention	42	53	irradiation
O	54	56	in
O	57	62	women
O	63	66	age
O	67	69	70
O	70	75	years
O	76	78	or
O	79	84	older
O	85	89	with
O	90	95	early
O	96	102	breast
O	103	109	cancer
O	109	110	:
O	111	115	long
O	115	116	-
O	116	120	term
O	121	127	follow
O	127	128	-
O	128	130	up
O	131	133	of
O	134	139	CALGB
O	140	144	9343
O	144	145	.

O	146	148	To
O	149	158	determine
O	159	166	whether
O	167	172	there
O	173	175	is
O	176	177	a
O	178	185	benefit
O	186	188	to
O	189	197	adjuvant
O	198	207	radiation
O	208	215	therapy
O	216	221	after
O	222	228	breast
O	228	229	-
O	229	239	conserving
O	240	247	surgery
O	248	251	and
O	252	261	tamoxifen
O	262	264	in
O	265	270	women
O	271	274	age
O	275	276	≥
O	277	279	70
O	280	285	years
O	286	290	with
O	291	296	early
O	296	297	-
O	297	302	stage
O	303	309	breast
O	310	316	cancer
O	316	317	.

O	318	325	Between
O	326	330	July
O	331	335	1994
O	336	339	and
O	340	348	February
O	349	353	1999
O	353	354	,
B-total-participants	355	358	636
O	359	364	women
O	365	366	(
O	366	369	age
B-age	370	371	≥
I-age	372	374	70
I-age	375	380	years
O	380	381	)
B-eligibility	382	385	who
I-eligibility	386	389	had
I-eligibility	390	398	clinical
I-eligibility	399	404	stage
I-eligibility	405	406	I
I-eligibility	407	408	(
I-eligibility	408	414	T1N0M0
I-eligibility	415	424	according
I-eligibility	425	427	to
I-eligibility	428	431	TNM
I-eligibility	432	446	classification
I-eligibility	446	447	)
I-eligibility	448	456	estrogen
I-eligibility	457	465	receptor
I-eligibility	466	467	(
I-eligibility	467	469	ER
I-eligibility	469	470	)
I-eligibility	471	472	-
I-eligibility	472	480	positive
I-eligibility	481	487	breast
I-eligibility	488	497	carcinoma
I-eligibility	498	505	treated
I-eligibility	506	508	by
I-eligibility	509	519	lumpectomy
O	520	524	were
O	525	533	randomly
O	534	542	assigned
O	543	545	to
O	546	553	receive
O	554	563	tamoxifen
O	564	568	plus
O	569	578	radiation
O	579	586	therapy
O	587	588	(
O	588	593	TamRT
O	593	594	;
B-intervention-participants	595	598	317
O	599	604	women
O	604	605	)
O	606	608	or
B-control	609	618	tamoxifen
I-control	619	624	alone
O	625	626	(
O	626	629	Tam
O	629	630	;
B-control-participants	631	634	319
O	635	640	women
O	640	641	)
O	641	642	.

O	643	650	Primary
O	651	654	end
O	655	661	points
O	662	666	were
B-outcome-Measure	667	671	time
I-outcome-Measure	672	674	to
I-outcome-Measure	675	680	local
I-outcome-Measure	681	683	or
I-outcome-Measure	684	692	regional
I-outcome-Measure	693	703	recurrence
O	703	704	,
B-outcome-Measure	705	714	frequency
I-outcome-Measure	715	717	of
I-outcome-Measure	718	728	mastectomy
O	728	729	,
B-outcome-Measure	730	736	breast
I-outcome-Measure	737	743	cancer
I-outcome-Measure	743	744	-
I-outcome-Measure	744	752	specific
I-outcome-Measure	753	761	survival
O	761	762	,
B-outcome-Measure	763	767	time
I-outcome-Measure	768	770	to
I-outcome-Measure	771	778	distant
I-outcome-Measure	779	789	metastasis
O	789	790	,
O	791	794	and
B-outcome-Measure	795	802	overall
I-outcome-Measure	803	811	survival
I-outcome-Measure	812	813	(
I-outcome-Measure	813	815	OS
I-outcome-Measure	815	816	)
O	816	817	.

O	818	824	Median
O	825	831	follow
O	831	832	-
O	832	834	up
O	835	838	for
O	839	846	treated
O	847	855	patients
O	856	858	is
O	859	862	now
O	863	865	12
O	865	866	.
O	866	867	6
O	868	873	years
O	873	874	.

O	875	877	At
O	878	880	10
O	881	886	years
O	886	887	,
B-iv-bin-percent	888	890	98
I-iv-bin-percent	890	891	%
O	892	894	of
O	895	903	patients
O	904	913	receiving
O	914	919	TamRT
O	920	921	(
O	921	923	95
O	923	924	%
O	925	927	CI
O	927	928	,
O	929	931	96
O	931	932	%
O	933	935	to
O	936	938	99
O	938	939	%
O	939	940	)
O	941	949	compared
O	950	954	with
B-cv-bin-percent	955	957	90
I-cv-bin-percent	957	958	%
O	959	961	of
O	962	967	those
O	968	977	receiving
O	978	981	Tam
O	982	983	(
O	983	985	95
O	985	986	%
O	987	989	CI
O	989	990	,
O	991	993	85
O	993	994	%
O	995	997	to
O	998	1000	93
O	1000	1001	%
O	1001	1002	)
O	1003	1007	were
B-outcome	1008	1012	free
I-outcome	1013	1017	from
I-outcome	1018	1023	local
I-outcome	1024	1027	and
I-outcome	1028	1036	regional
I-outcome	1037	1048	recurrences
O	1048	1049	.

O	1050	1055	There
O	1056	1060	were
O	1061	1063	no
O	1064	1075	significant
O	1076	1087	differences
O	1088	1090	in
B-outcome	1091	1095	time
I-outcome	1096	1098	to
I-outcome	1099	1109	mastectomy
O	1109	1110	,
B-outcome	1111	1115	time
I-outcome	1116	1118	to
I-outcome	1119	1126	distant
I-outcome	1127	1137	metastasis
O	1137	1138	,
B-outcome	1139	1145	breast
I-outcome	1146	1152	cancer
I-outcome	1152	1153	-
I-outcome	1153	1161	specific
I-outcome	1162	1170	survival
O	1170	1171	,
O	1172	1174	or
B-outcome	1175	1177	OS
O	1178	1185	between
O	1186	1189	the
O	1190	1193	two
O	1194	1200	groups
O	1200	1201	.

B-outcome	1202	1205	Ten
I-outcome	1205	1206	-
I-outcome	1206	1210	year
I-outcome	1211	1213	OS
O	1214	1217	was
B-iv-bin-percent	1218	1220	67
I-iv-bin-percent	1220	1221	%
O	1222	1223	(
O	1223	1225	95
O	1225	1226	%
O	1227	1229	CI
O	1229	1230	,
O	1231	1233	62
O	1233	1234	%
O	1235	1237	to
O	1238	1240	72
O	1240	1241	%
O	1241	1242	)
O	1243	1246	and
B-cv-bin-percent	1247	1249	66
I-cv-bin-percent	1249	1250	%
O	1251	1252	(
O	1252	1254	95
O	1254	1255	%
O	1256	1258	CI
O	1258	1259	,
O	1260	1262	61
O	1262	1263	%
O	1264	1266	to
O	1267	1269	71
O	1269	1270	%
O	1270	1271	)
O	1272	1274	in
O	1275	1278	the
O	1279	1284	TamRT
O	1285	1288	and
O	1289	1292	Tam
O	1293	1299	groups
O	1299	1300	,
O	1301	1313	respectively
O	1313	1314	.

O	1315	1319	With
O	1320	1324	long
O	1324	1325	-
O	1325	1329	term
O	1330	1336	follow
O	1336	1337	-
O	1337	1339	up
O	1339	1340	,
O	1341	1344	the
O	1345	1355	previously
O	1356	1364	observed
O	1365	1370	small
O	1371	1382	improvement
O	1383	1385	in
B-outcome	1386	1398	locoregional
I-outcome	1399	1409	recurrence
O	1410	1414	with
O	1415	1418	the
O	1419	1427	addition
O	1428	1430	of
O	1431	1440	radiation
O	1441	1448	therapy
O	1449	1456	remains
O	1456	1457	.

O	1458	1465	However
O	1465	1466	,
O	1467	1471	this
O	1472	1476	does
O	1477	1480	not
O	1481	1490	translate
O	1491	1495	into
O	1496	1498	an
O	1499	1508	advantage
O	1509	1511	in
O	1512	1514	OS
O	1514	1515	,
O	1516	1523	distant
O	1524	1531	disease
O	1531	1532	-
O	1532	1536	free
O	1537	1545	survival
O	1545	1546	,
O	1547	1549	or
O	1550	1556	breast
O	1557	1569	preservation
O	1569	1570	.

O	1571	1580	Depending
O	1581	1583	on
O	1584	1587	the
O	1588	1593	value
O	1594	1600	placed
O	1601	1603	on
O	1604	1609	local
O	1610	1620	recurrence
O	1620	1621	,
O	1622	1625	Tam
O	1626	1633	remains
O	1634	1635	a
O	1636	1646	reasonable
O	1647	1653	option
O	1654	1657	for
O	1658	1663	women
O	1664	1667	age
O	1668	1669	≥
O	1670	1672	70
O	1673	1678	years
O	1679	1683	with
O	1684	1686	ER
O	1686	1687	-
O	1687	1695	positive
O	1696	1701	early
O	1701	1702	-
O	1702	1707	stage
O	1708	1714	breast
O	1715	1721	cancer
O	1721	1722	.
